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Abstract
Objective—Low-density lipoprotein cholesterol (LDL-C) is a risk factor for survival in middle-
aged individuals, but conflicting evidence exists on the relationship between LDL-C and all-cause 
mortality among the elderly. The goal of this study was to assess the relationship between LDL-C 
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and all-cause mortality among Chinese oldest old (aged 80 and older) in a prospective cohort 
study.
Methods—LDL-C concentration was measured at baseline and all-cause mortality was 
calculated over a 3-year period. Multiple statistical models were used to adjust for demographic 
and biological covariates.
Results—During three years of follow-up, 447 of 935 participants died, and the overall all-cause 
mortality was 49.8%. Each 1 mmol/L increase of LDL-C concentration corresponded to a 19% 
decrease in 3-year all-cause mortality (hazard ratio [HR] 0.81, 95% confidence interval [CI] 0.71–
0.92). The crude HR for abnormally higher LDL-C concentration (≥3.37 mmol/L) was 0.65 (0.41–
1.03); and the adjusted HR was statistically significant around 0.60 (0.37–0.95) when adjusted for 
different sets of confounding factors. Results of sensitivity analysis also showed a significant 
association between higher LDL-C and lower mortality risk.
Conclusions—Among the Chinese oldest old, higher LDL-C level was associated with lower 
risk of all-cause mortality. Our findings suggested the necessity of re-evaluating the optimal level 
of LDL-C among the oldest old.
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Introduction
Low-density lipoprotein cholesterol (LDL-C) is a risk factor for cardiovascular and 
cerebrovascular diseases and is associated with increased mortality in middle-aged 
individuals [1]. For the elderly, however, there are three concerns that cast doubt on the 
applicability of general LDL-C recommendations. First, studies of older populations have 
led to conflicting conclusions on the relationship between LDL-C and all-cause mortality. 
Some studies showed that high concentrations of LDL-C were associated with higher risk of 
mortality and morbidity of cardiovascular and cerebrovascular diseases or all-cause 
mortality among the elderly [2, 3], while other studies found that low LDL-C concentrations 
were associated with increased mortality risk from non-cardiovascular disease [4], such as 
cancer [5], infection [6], liver diseases [7], and trauma [8] among elderly. Several studies 
also concluded that LDL-C was inversely associated with the risk of death in elderly people 
[9–14], which has attracted particular attention regarding the necessity for LDL-C lowering 
therapy in the aged population.
A second concern about the generalizability of lipid treatment recommendations is that most 
studies have been conducted in high-income countries. Understanding this relationship in 
low-income and heavily populated countries is particularly urgent as they confronting the 
challenge of a rapidly increasing aging population.
A third concern is that currently almost all the recommendations to lower the level of LDL-
C were formulated for the general adult population [15–17], and there were very few studies 
that focused on the optimal LDL-C level of the oldest old. To investigate this question, we 
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assessed the relationship between LDL-C and all-cause mortality in a longitudinal cohort of 
oldest old in China.
Methods
Study Design and Participants
We used data collected in the Chinese Longitudinal Healthy Longevity Survey (CLHLS). 
The study design of CLHLS has been described in detail elsewhere [18]. The baseline 
survey of this current study was conducted in 2009, in 7 longevity areas of China, and 935 
aged 80 years or older participated in the baseline survey, including 319 octogenarians, 276 
nonagenarians and 340 centenarians. The follow-up survey was conducted in 2012. The 
study was approved by the Ethics Committee of Peking University and the Ethics 
Committee of the National University of Singapore. Written consent was obtained from all 
participants.
Participants were followed-up for a length of 38 months from the baseline survey in June 
2009 to August 2012. Participants’ survival status was ascertained during the follow-up 
survey. Dates of death were acquired and confirmed by participants’ family members or the 
village doctor. The information on cause-specific death was not collected in this study 
because (1) the seven survey fields are not covered by the death surveillance system in 
China, (2) reported conditions prior to death do not provide clear insight into the cause of 
death in the oldest old with a variety of chronic diseases, and (3) many of the oldest old die a 
natural death at home rather than in hospital where cause of death may be assessed. A ‘lost-
to-follow-up’ status was assigned to those who could not be found and contacted.
Data Collection
Baseline assessments included a researcher-administered questionnaire, physical 
examination, and laboratory testing. All the questions were answered by the participants 
themselves or with their family members if the participants were unable to complete 
interviews. The following information was collected: socioeconomic and demographic 
characteristics, dietary behaviors and life style, diseases, cognitive function, and the 
performance of activities of daily living (ADL).
Physical examination was performed to measure systolic blood pressure (SBP), diastolic 
blood pressure (DBP), waist circumference (WC), and vision. Five milliliters of venous 
blood and 15 milliliters of urine were collected in the morning after an overnight fast for at 
least 12 hours. Serum creatinine was determined with the picric acid method and 
albuminuria was measured by dry chemistry reagent test strips (Siemens Diagnostics, NY, 
USA). Fasting plasma glucose, hemoglobin, LDL-C and high-density lipoprotein cholesterol 
(HDL-C) were measured by an Automatic Biochemistry Analyzer (Hitachi 7180, Japan) 
using commercially available diagnostic kits (Roche Diagnostic, Mannheim, Germany) at 
Capital Medical University in Beijing.
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Key Variables and Definitions
The Mini-Mental Status Examination was used to define cognitive impairment (score: 0–17) 
[19]. Activity of daily living (ADL) was assessed based on self-reported performance of the 
following six self-care tasks: dressing, eating, toileting, bathing, indoor activities, and 
continence. ADL was defined as normal if an individual could deal with all six tasks 
independently; otherwise ADL was defined as restricted [20].
Hypertension was defined as systolic blood pressure≥140mmHg and/or diastolic blood 
pressure≥90mmHg, and/or being on antihypertensive therapy. Central obesity was defined 
as waist circumference ≥85cm in men or waist circumference ≥80cm in women participants. 
Type 2 diabetes mellitus was defined as fasting plasma glucose≥7.0 mmol/L or self-report of 
current diabetes related medication use. Anemia was defined as hemoglobin <130g/L in men 
or hemoglobin <120g/L in women. Abnormally high LDL-C level was defined as ≥3.37 
mmol/L, and low HDL-C was defined as <1.04 mmol/L (15). Different LDL-C levels cut 
points were used to define higher LDL-C level, including LDL-C≥3.12 mmol/L and LDL-
C≥2.85 mmol/L. Chronic kidney disease (CKD) was assessed from estimated glomerular 
filtration rate (eGFR) less than 60 ml/min per 1.73 m2 and/or albuminuria [21]; The eGFR 
was calculated with the modification of diet in renal disease (MDRD) equations for Chinese: 
eGFR=175 (serum creatinine)−1.234 ×age−0.179×0.79(if female) [22].
Statistical Analysis
The characteristics of participants were compared using t-test for continuous variables and 
Chi-square tests for categorical variables between death versus survival, and survival versus 
lost-to-follow-up, respectively. Mortality rate for 100-person-years was calculated by the 
life table method, which was partly adjusted for the influence of lost-to-follow-up.
The survival time was calculated from the date of the baseline survey to the date of death, 
and was defined as 38 months for those censored participants who survived or were lost-to-
follow-up. Survival rate was estimated with the Kaplan-Meier product-limit method, and 
compared with the log-rank test. Schoenfold residual error method was used for the 
proportional hazards assumption test; the correlation coefficient was 0.04 and the p value 
was 0.35, which showed that it met the proportional hazards assumption. Crude and adjusted 
HRs for LDL-C concentrations were estimated using Cox proportional hazards models. In 
Model 1, HRs were adjusted for sex, age and marital status were adjusted. And current 
smoking, current alcohol drinking, and tea drinking were further included in Model 2. 
Central obesity, cognitive impairment, ADL restriction and blindness were further added in 
Model 3. Anemia, hypertension, type 2 diabetes mellitus, CKD and HDL-C were 
additionally added in the Model 4.
To address whether the associations between LDL-C and mortality were stable, models were 
performed using different LDL-C concentrations as cut points. To explore gender 
differences and the possibility that low LDL-C concentration may be a consequence of acute 
disease that causes increased mortality, these analyses were also stratified by gender and by 
excluding deaths in the first year of follow-up. To clarify the effect of lost-to-follow-up on 
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the results, sensitivity analyses were conducted by censoring lost-to-follow-up at baseline (0 
month) or follow-up assessment (38 months), or at the midpoint of follow-up (19 months).
Statistical analyses were performed with SAS, version 9.13 (SAS Institute Inc, Cary, NC, 
USA). 2-sided p value <0.05 was considered significant
Results
A total of 935 participants aged 80 years or older were enrolled in the baseline survey in 
2009. The mean age of the participants was 94.2 years, and 69% of them were women. 
Approximately 8% (73/935) of participants were lost-to-follow-up. A total of 862 
participants were successfully followed-up, and 447 died. Characteristics of those who 
survived, died or were lost-to-follow-up were compared (Table 1). The mean baseline age of 
those who died was significantly higher than those who survived. The mean baseline values 
of hemoglobin, systolic blood pressure, diastolic blood pressure and LDL-C were lower 
among those who died compared to those who survived. Participants who survived had a 
higher prevalence of central obesity, lower prevalence of cognitive impairment, ADL 
restrictions, blindness, and CKD than those who died. No significant difference was found 
for all covariates between those who survived and those who were lost-to-follow-up.
The all-cause mortality rate in 3 years was 21.4 per 100 person-years for all subjects, 19.6 
for males and 22.3 for females; and it was 12.1 per 100 person-years for octogenarians, 20.9 
for nonagenarians and 33.1 for centenarians (Figure 1).
The average LDL-C level was 2.06 mmol/L for all participants, 1.87 and 2.14 mmol/L for 
men and women, respectively. The prevalence of abnormally high LDL-C (≥3.37 mmol/L) 
was 5.7% for all participants, and 3.4% for men and 6.6% for women. The average LDL-C 
level was lower among participants who died (2.00 mmol/L) than those who survived (2.10 
mmol/L) (p=0.04).
When LDL-C was analyzed as a continuous variable, each 1 mmol/L increase in LDL-C 
corresponded to an 18% relative decrease in mortality risk for all participants with HR [95% 
CI] 0.81 [0.71–0.92] for all participants ( 0.71 [0.53–0.96] for men, and 0.80 [0.69–0.93] for 
women).
The crude mortality risk ratio for an abnormally high LDL-C concentration (≥3.37 mmol/L) 
was 0.65 (0.41–1.03). When demographic variables were adjusted (Model 1), those who had 
an abnormally higher LDL-C level had a 40% lower risk of mortality than those had a lower 
level of LDL-C (HR, 0.60; 95% CI, 0.38–0.96). The inverse association remained 
statistically significant after further adjusting for other variables (Table 2). Figure 2 shows 
the survival curves for the oldest old with lower and abnormally higher baseline LDL-C 
levels.
We further examined the mortality risk for different cutoff values of LDL-C concentrations 
(Table 3). At all cutoff values, participants with higher LDL-C levels had a significantly 
lower risk of mortality compared to those with lower LDL-C levels. After excluding those 
who died during the first year of follow-up, censoring at 19 months, or deleting all lost-to-
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follow-up, the significant associations were marginally significant but the significant 
association of higher concentrations of LDL-C with mortality risk remained. The results for 
each 1 mmol/L increase of LDL-C concentration with mortality risk also remained 
significant or marginally significant (Table 3 and 4).
Discussion
Our results indicated that a higher level of LDL-C was inversely associated with 3-year all-
cause mortality among the Chinese oldest old. Compared with participants who had a lower 
LDL-C, those with high concentrations had a 40% lower mortality risk, which was 
consistent with several other studies [9–14, 21]. A follow-up study in France reported that 
lower level of LDL-C was associated with increased mortality risk for hospitalized elderly 
patients [11]. Studies further demonstrated that higher LDL-C was associated with reduced 
risk of mortality for both Japanese very elderly [13] and oldest old [23]. This phenomenon 
was also found in an elderly Brazilian cohort [9], elderly Italian women [14], non-demented 
elderly [11] and elderly patients with heart failure [12] in the United States.
There are several possible explanations for the inverse association between LDL-C level and 
mortality risk, First, evidence from animal experiments and epidemiological studies 
suggested that higher LDL-C affects the immune system, which may improve survival 
through enhanced defense against bacteria and viruses, or by raising delivery of lipids to 
cells which may promote the immune response as well as tissue repair [24]. Furthermore, a 
cohort study demonstrated that high LDL-C may improve the odds of survival in the context 
of fever and sepsis [6].
Second, epidemiological studies suggest that low LDL-C in the oldest old may exert an 
indirect effect to increase non-cardiovascular mortality [4]. It was not possible to establish a 
direct link of low LDL-C to an adverse effect on vascular mortality or non-vascular 
mortality because of the unavailable cause-specific mortality in our study. Some studies 
found low LDL-C was an independent predictor of depression [25], cancer [5], injury, 
homicides and suicide [26]. In other studies, LDL-C was reported to have an inverse 
association with death from liver diseases [7], intra parenchymal haemorrhage [27], and 
advanced chronic kidney disease [28].
Third, LDL-C was highly correlated to total cholesterol and among the oldest old, low total 
cholesterol was associated with increased mortality in the oldest old [29]. This phenomenon 
was also found by other studies of elderly [30] and middle aged [31] people.
Fourth, perhaps individuals susceptible to the vascular effects of high LDL-C had already 
died before aged 80 years, and thus were not included in the sample. The individuals who 
remained would be a select group with lower cholesterol whose genetic makeup or other 
factors protect them from the effects of high LDL-C level and thereby enhance survival. To 
a certain extent our data supported this hypothesis, the concentrations of LDL-C in the 
oldest old was very low in our study.
Several studies show that higher LDL-C increased all-cause mortality and lower LDL-C is 
beneficial in the elderly [3, 4]. A possible explanation for the different results in the present 
LV et al. Page 6
Atherosclerosis. Author manuscript; available in PMC 2015 May 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
study is that, unlike the studies noted, we focus on the oldest old and have sufficient 
numbers aged 80 years and older to make meaningful conclusions. It is likely that successful 
aging of the oldest old may depend on a complex restructuring of physiological mechanism 
and adaptation of metabolism, it is likely that their metabolism is able to adapt to the 
challenges of aging, detrimental factors during early and middle ages may become 
protective in later life.
Moreover, it is also notable that a relatively lower LDL-C in the oldest old is extensively 
advertised in some communities even though this age-group is not well represented in 
epidemiological or clinical trials. But according to our study, and those of others, keeping 
higher LDL-C rather than lower concentration is beneficial to their survival for those aged 
80 years or older. More epidemiological and clinical data are needed for primary prevention 
of mortality in the oldest old.
Strengths and Limitations
This is the first study using a relatively large sample of oldest old to investigate the 
associations of LDL-C and all-cause mortality. It is a longitudinal prospective study, which 
has a greater power to assess the epidemiological association between LDL-C and mortality.
This study has several limitations. We did not investigate treatment with lipid-lowering 
drugs, but it likely had little effect on our results because only a few participants reported 
being diagnosed by a doctor as having dyslipidemia. Exploration of potential intermediate 
variables, such as the diseases causing death, was not performed because of the unavailable 
cause-specific mortality data. In addition, our study was focused on Chinese oldest old, so 
our results may not be applicable to other ethnic or age groups.
Conclusions
In conclusion, our cohort study provides epidemiological evidence that higher levels of 
LDL-C were associated with better survival among the oldest old. We suggest that more 
interventional studies are needed to elucidate the clinical effects of higher LDL-C level in 
the oldest old.
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Figure 1. 
3-year all-cause mortality rate (person-year) among Chinese oldest old by gender
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Figure 2. 
Survival curves for Chinese oldest old stratified by baseline LDL-C level
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